WaveSense, Inc. Announces The Launch Of A New Application that Targets, Enriches and Isolates Cells Obtained From DRE/DRM

BOSTON, March 23, 2015 /PRNewswire/ -- USCAP Annual Meeting -- WaveSense, Inc., the leader in targeted cell enrichment and isolation, announced today the availability of the latest addition to its line of cell enrichment applications delivered through its patented EpiSep® medical product line.

The Cell Enrichment from Expressed Prostate Secretions ("EPS") application captures, enriches and isolates targeted cells contained in prostate secretions obtained through digital rectal examination (DRE) or digital rectal massage (DRM).  The EPS application is an important new addition to the WaveSense's Urology application suite that already includes cell enrichment from urine.

"We felt that the USCAP Annual Meeting was the perfect venue to unveil this important new application…one that may provide pathologists and urologists with vital new insights into patient management," stated Chris Feistel, the Chief Executive Officer of WaveSense.

Dr. Felipe Dominquez, President and Medical Director of Suncoast Pathology Associates in Melbourne, Florida, noted that, "Managing patients with elevated PSA, prostatitis, microhematuria and post-negative prostate biopsy results by non-invasively capturing, identifying and differentiating normal prostate epithelial cells from those with chromosomal aberrations is a game-changer."

Dr. Shahnaz Saeed, Medical Director of the Metro Chicago Surgical Oncology, Pathology Laboratory in Wilmette, Illinois, observed, "The ability to capture, enrich and isolate prostate epithelial cells from Expressed Prostate Secretions obtained through DRM could be an important non-invasive active surveillance tool." 

The Cell Enrichment from Expressed Prostate Secretions application is the latest addition to a growing list of EpiSep HS^® targeted cell enrichment and isolation applications, including its Cell Enrichment from Urine (Uro-1) and Cell Enrichment from Bone Marrow (CD138) applications. 

For more information about the EPS application, including a tutorial entitled "General Procedure for Isolation of Target Cells from Expressed Prostate Secretions Following DRE or DRM", please select the following link to the WaveSense website: www.wavesense.com/support_tutorials.htm

About WaveSense, Inc.

WaveSense, Inc. is a leading manufacturer of In Vitro Diagnostic (IVD) cell targeting, enrichment and isolation products for pathology, urology and oncology.  Our patented EpiSep HS^® device targets, captures, enriches and isolates "cells of interest" while simultaneously eliminating unnecessary and unwanted background cells.  This important new capability is essential to realize the potential of next-generation liquid biopsy applications. Without the need for expensive capital equipment outlays, the EpiSep direct-to-slide cell enrichment and isolation technology easily optimizes clinical specimens for downstream applications such as FISH, IHC and other methodologies that benefit from the enrichment of target cells and the elimination of background cells.  WaveSense is the unquestioned leader in next-generation Targeted Cell Enrichment and Isolation for Liquid Biopsy applications.  For more information, visit WaveSense at: www.wavesense.com

SOURCE WaveSense, Inc.

Related Links

http://www.wavesense.com